Table 1.
Demographics and clinical information.
| Healthy controls | RLS patients | p-value1 | |
|---|---|---|---|
| Sample size (N) | 72 | 72 | |
| Age (years), median (IQR) | 51.0 (46.4–57.9) | 51.9 (46.6–59.7) | 0.52 |
| Sex (male/female) | 35/37 | 35/37 | 1.00 |
| Onset (early/late) | – | 46/26 | |
| Age at onset (years), median (IQR) | – | 37.0 (28.0–48.5) | |
| Disease duration (years), median (IQR) | – | 14.8 (5.0–21.0) | |
| Drug status (untreated/dopaminergic) | – | 29/43 | |
| CGI, median (IQR) | – | 3.5 (3.0–4.0) | |
| IRLS, median (IQR) | – | 13.7 (7.0–21.5) | |
| RLS-6, median (IQR) | – | 15.0 (8.0–20.0) | |
| Family history (yes/no) | – | 28/44 | |
| Iron (umol/L), median (IQR) | 17.6 (13.6–20.7) | 18.0 (15.4–20.5) | 0.38 |
| Ferritin (ug/L), median (IQR) | 109.9 (46.8–160.2) | 129.6 (52.5–154.5) | 0.50 |
| Transferrin (mg/dL), median (IQR) | 263.9 (243.0–281.0) | 266.9 (235.0–293.0) | 0.88 |
| Transferrin saturation (%), median (IQR) | 27.1 (21.0–32.0) | 27.6 (20.0–33.2) | 0.62 |
CGI: clinical global impression (0–7); IQR: Interquartile range; IRLS: International Restless Legs Syndrome Study Group rating scale; RLS: restless legs syndrome; RLS-6: Restless Legs Syndrome-6 Scale (0–60); Early onset was defined as before 45 years of age.
1
Wilcoxon rank sum test; Pearson's Chi-squared test.